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and M eic H. Schmidt, M.D.
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Object. Spinal cord compression is one of the most dreaded complications of metastatic cancer. It can lead to a num­
ber of sequelae, including pain, spinal instability, neurological deficits, and a reduction in the patient’s quality of life. 
Except in selected circumstances, treatment is palliative. Treatment options include surgery, radiation, and chemother­
apy. The goal of this study was to summarize the existing data on the outcomes of various treatment methods for met­
astatic spinal epidural disease and to make appropriate recommendations for their use.
Methods. The authors used a search strategy that included an electronic database search, a manual search of jour­
nals, analysis of bibliographies in relevant review papers, and consultation with the senior author. There is good evi­
dence, including Class I data, that steroid drugs constitute a beneficial adjunctive therapy in patients with myelopathy 
from epidural compression. Historically, conventional radiation therapy has been viewed as the first-line treatment 
because it has been shown to be as effective as a decompressive laminectomy, with a lower incidence of complications 
(Class II data). Nevertheless, in the last 20 years there has been remarkable progress in surgical techniques and tech­
nology. Currently, the goals of surgery are to achieve a circumferential decompression of the spinal cord, and to recon­
struct and immediately stabilize the spinal column. Results in a large body of literature support the belief that surgery 
is better at retaining or regaining neurological function than radiation and that surgery is highly effective in relieving 
pain. Most of the data on the treatment of metastatic spinal disease are Class II or III, but the preliminary results of a 
well-designed, randomized controlled trial in which surgery is compared with standard radiation therapy represents the 
first Class I data.
Conclusions. As the number of treatment options for metastatic spinal disease has grown, it has become clear that 
effective implementation of these treatments can only be achieved by a multidisciplinary approach.
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In approximately 50 to 70% of patients with cancer there 
is evidence of metastatic disease at the time of death.36 
The spinal column is the most common osseous site, and 
may be involved in up to 40% of patients with cancer.11,89 
Not all spinal metastases will lead to neurological dys­
function, however. Epidural spinal cord compression from 
metastases occurs in 5 to 10% of cancer patients and in up 
to 40% of patients with preexisting nonspinal bone metas­
tases.6’8’15’26’38’89 Of those with spinal disease, 10 to 20% 
will experience symptomatic spinal cord compression, re­
sulting in more than 25,000 cases per year; this number is 
expected to grow.28,50,72
The thoracic spine is the most common site of disease 
(70%), followed by the lumbar (20%) and cervical spine 
(10%).15,28’29 Metastatic spinal disease can arise from one 
of three locations: the vertebral column (85%), the para­
vertebral region (10-15%), and, rarely, the epidural or 
subarachnoid/intramedullary space itself (<  5%).15,28,29 
The posterior half of the VB is usually involved first, with 
the anterior body, lamina, and pedicles invaded later.1 In-
Abbreviation used in this paper: VB = vertebral body.
tradural (including intramedullary) metastases from non- 
neural primary tumors are extremely rare, but have been 
reported.41,73 Multiple lesions at noncontiguous levels oc­
cur in 10 to 40% of cases.1519,28’29
Approximately 50% of spinal metastases arise from 
one of three primary sites: breast, lung, or prostate.15 
These are followed by renal, gastrointestinal, thyroid, sar­
coma, and the lymphoreticular malignancies lymphoma 
and multiple myeloma. Metastases from prostate, breast, 
melanoma, and lung lesions commonly cause spinal tu­
mors in 90.5, 74.3, 54.5, and 44.9% of patients, respec­
tively.89 The incidence of neurological deficits caused by 
epidural spinal cord compression varies, however, with 
the site of primary disease as follows: 22% of patients 
with breast cancer, 15% with lung cancer, and 10% with 
prostate cancer.28 In the past, neurological dysfunction and 
spine pain would have been the first manifestation of their 
cancer in up to 70% of patients.1314,79’82 In these cases, the 
lung was the primary source of malignancy more than 
50% of the time.28,79
Treatment for spinal metastases is frequently palliative. 
Only in selected cases, usually with renal cell carcinoma,
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can cure be the goal if the spine is the only known site of 
disease.12 Treatment can be broadly categorized as che­
motherapy, radiation, and surgery. In this article we sum­
marize the existing data on these treatment modalities 
and provide appropriate recommendations on their indi­
cations.
CLINICAL MATERIAL AND METHODS
Search Strategy
The goal of the search strategy was to identify articles 
in which the effectiveness of various treatments for meta­
static spinal disease, specifically surgery, radiation, and 
chemotherapy (steroid drugs only) is assessed. The search 
strategy included an electronic database search, a manual 
search of journals, analysis of bibliographies in relevant 
review papers, and consultation with the senior author 
(M.H.S.). For the electronic search we used Medline 
(PubMed) to identify articles published between 1966 and 
August 2003 in which the following terms were used in 
various combinations: “spine,” “metastases,” “radiation,” 
“surgery,” “steroids,” “treatment,” “cancer,” “decompres­
sion,” “laminectomy,” “stereotactic radiosurgery,” and 
“vertebrectomy.” Papers were also found using the “Relat­
ed Articles” function on PubMed. Articles were reviewed 
and the data were abstracted by the primary and senior 
authors (P.K., M.H.S.).
Assessment o f  Literature Quality and Treatment 
Recommendations
The quality of the literature and thus the strength of 
treatment recommendations was assessed using defini­
tions set forth by Woolf, et al.,90 and used by Loblaw and 
Laperriere55 in their review of the literature on the meta­
static spine. The definitions of the different classes of evi­
dence denoting literature quality and strength of treatment 
recommendations are shown in Tables 1 and 2.
Outcome Measures
The primary outcome measure for this literature review 
was ambulatory status. In most articles this was reported 
directly, whereas in other articles this number was calcu­
lated from the neurological grading schemes that were 
used, such as the Frankel system (Table 3).26 Once the 
ambulatory status before and after treatment was deter-
TABLE 1
Classification o f evidence on therapeutic effectiveness o f treat­
ments for metastatic spinal disease
Evidence
Class Definition
I evidence obtained from > 1 properly designed randomized 
controlled trial
II evidence obtained from well-designed, controlled trials w/o
randomization, such as nonrandomized cohort studies, case- 
control studies, & other comparable studies, including less 
well-designed randomized controlled trials 
III evidence from case series, comparative studies w/ historical 
controls, case reports, & expert opinion, as well as signifi­
cantly flawed randomized controlled trials
TABLE 2




A good evidence (Class I) to support the recommendation that 
the maneuver be specifically considered as an intervention 
for the condition
B fair evidence (Class II) to support the recommendation that 
the maneuver be specifically considered as an intervention 
for the condition
C poor evidence (Class III) to support the recommendation that 
the maneuver be specifically considered as an intervention 
for the condition or that it confers no advantage over com­
peting interventions*
D fair evidence (Class II) to support the recommendation that 
the maneuver be excluded from consideration as an inter­
vention for the condition 
E good evidence (Class I) to support the recommendation that 
the maneuver be excluded from consideration as an inter­
vention for the condition
* Considering efficacy of the intervention with regard to primary out­
come, and side effects of the intervention. The physician may then want to 
take into consideration other outcomes, such as cost convenience, resource 
allocation, and other aspects of feasibility.
mined, we calculated two further variables in selected 
studies: the “success” and “rescue” rates. The success rate 
is defined as the proportion of all patients within the study 
who retained or regained ambulatory function after treat­
ment. The rescue rate is the percentage of patients who 
were nonambulatory before treatment, but who regained 
the ability to walk, either with assistance or independently.
Secondary outcomes included pain, treatment-related 
morbidity, survival, and autonomic function. These out­
comes were not universally reported in the literature re­
viewed here and will therefore only be mentioned with 
reference to specific articles.
RESULTS
Steroid Medications
Best Level of Evidence, Class I; Level of Recommenda­
tion, A. There is good evidence to support the use of 
steroid drugs in patients with newly diagnosed metastatic 
spinal disease causing spinal cord dysfunction. It should 
be noted that in patients with no history of cancer who 
present with an undiagnosed spinal mass, especially 
younger patients, steroid drugs should be avoided until the 
diagnosis is made. The reason for this is that for some 
tumors, particularly lymphomas and thymomas, steroid 
medications have an oncolytic effect that may cause a 
delay in diagnosis.9 Dexamethasone is the most widely 
used steroid, although methylprednisolone, which is more 
commonly prescribed in trauma, has also been used. Ste­
roid drugs have been shown to reduce vasogenic edema, 
protect against lipid peroxidation and lipid hydrolysis, 
prevent ischemia and intracellular calcium accumulation, 
and support cellular energy metabolism.3
The optimal dosage of dexamethasone in metastatic 
spinal cord compression is controversial. Loading doses 
range from 10 to 100 mg, followed by 4 to 24 mg four 
times a day, tapering down over several weeks.9,15,29,31'
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Modified Frankel neurological functional classification
Grade Description
A no motor or sensory function
B preserved sensation only, no motor function
C nonambulatory, wheelchair-bound, some motor function
a bowel or bladder paralysis
b neurogenic bowel or bladder
c voluntary normal bowel or bladder function
D ambulatory but w/ neurological symptoms
1 requires walker
2 requires cane
3 can walk independently
a bowel or bladder paralysis
b neurogenic bowel or bladder
c voluntary, normal bowel or bladder function
E normal neurological function
57,64,78 Many practitioners use the larger doses for patients 
who present with severe baseline symptoms or worsening 
neurological examination. Some advocate using the trau­
ma dose protocol in patients with rapid neurological dete- 
rioration.62 In a well-designed, randomized controlled 
study in which high-dose dexamethasone followed by 
radiotherapy was compared to radiotherapy alone, 81% 
of patients in the steroid treatment group were ambulato­
ry posttreatment compared with 63% of patients treated 
with radiation alone.78 In another randomized controlled 
trial, patients with a complete myelographically con­
firmed block who received a 100-mg bolus of dexametha- 
sone followed by a standard maintenance dose had no bet­
ter pain relief, ambulation, or bladder function compared 
with those who received a 10-mg bolus and the same 
maintenance therapy.84 It is clear, however, that higher 
doses are associated with more complications.39 There­
fore, based on this information, an appropriate regimen 
of dexamethasone would be an initial bolus of 10 mg fol­
lowed by 16 mg/day, tapering over several weeks.
Surgery: Posterior Decompressive Laminectomy
Best Level of Evidence, Class II; Level of Recommen­
dation, D. For many years, laminectomy was the only sur­
gical option offered to patients with metastatic spinal dis­
ease. In fact, in this context, the term “surgery” is to some 
extent still equated with laminectomy, contributing to the 
bias in favor of radiotherapy. One of the reasons laminec­
tomy was the dominant surgical procedure was because of 
its relative ease. It can be performed quickly by any neu­
rosurgeon with minimal intraoperative risk to the patient, 
and it does not require spinal column reconstruction or 
placement of internal stabilization devices. Despite its 
widespread use, there was no consensus among surgeons 
regarding its effectiveness. Some thought that it was the 
only reasonable hope for treating neurological deficits, 
whereas others found it to be of little value except for ob­
taining tissue to make a diagnosis and for relieving pain.10
Much of the existing literature on decompressive lami­
nectomy consists of uncontrolled cohort studies (Class 
III). Recorded outcomes usually include ambulatory sta­
tus before and after treatment, pain relief, and treatment- 
related complications. As can be seen in Table 4, 14 to
58% of patients who underwent a posterior decompressive 
laminectomy were ambulatory postsurgery. Not shown 
in the table, however, are the significant nonneurologi- 
cal complications that follow laminectomy, specifically 
wound infection/dehiscence and spinal instability. In a re­
view of the literature by Findlay,23 the incidence of non- 
neurological complications was found to be approximate­
ly 11%.
In a number of articles, including controlled cohort 
studies (Class II), the efficacy of laminectomy alone has 
been compared with radiation alone and with laminecto­
my followed by radiation.10,18,23,29,58,77,79,92 One of these, 
by Gilbert, et al.,29 was a single-institution, retrospective 
analysis of 235 patients treated with either decompressive 
laminectomy followed by radiation (65 patients) or radia­
tion alone (170 patients). After treatment, 46% of those 
who underwent combination therapy were ambulatory 
compared with 49% of those who underwent radiation 
alone. Pretreatment neurological function was the most 
reliable indicator of posttreatment function. There was no 
significant difference in the rate of neurological recovery
TABLE 4
Ambulatory outcome after various treatments for spinal 
cord compression
Treatment No. of Success Mean
Authors & Year Patients (%)* (%)
posterior decompressive laminectomy alone 30
Barron, et al., 1959 38 29
Wild & Porter 1963 22 26
Wright, 1963 21 14
Brice & McKissock, 1965 139 32
Smith, 1965 52 25
Auld & Buerman, 1966 41 42
Hall & Mackay, 1973 129 30
Livingston & Perrin, 1978 100 58
Baldini, et al., 1979 140 30
Dunn, et al., 1980 104 33
Stark, et al., 1982 32 16
Findlay, 1987 80 24
Sorensen, et al., 1989 105 34
radiation therapy alone 47
Mones, et al., 1966 41 34
Khan, et al., 1967 82 41
Posner, 1971 75 47
Cobb, et al., 1977 18 50
Gilbert, et al., 1978 170 49
Greenberg, et al., 1980 83 57
Stark, et al., 1982 32 35
Constans, et al., 1983 108 39
Martenson, et al., 1985 42 64
Ruff & Lanska, 1989 41 73
Sorensen, et al., 1990 149 38
posterior decompressive laminectomy & radiation therapy 47
Mullan & Evans, 1957 21 43
Wild & Porter, 1963 23 44
Wright, 1963 17 47
Gilbert, et al., 1978 65 45
Stark, et al., 1982 52 37
Constans, et al., 1983 465 46
Martenson, et al., 1985 21 57
Sherman & Waddell, 1986 111 57
Sorensen, et al., 1990 91 53
* “Success” is defined as the ability to walk after the operation (that is, 
gait was maintained, improved, or regained as a result of the laminectomy).
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between the two groups. Of the 22 patients in whom rap­
idly progressive weakness developed ( 48 hours), nine 
underwent surgery and 13 received radiation therapy. 
None of the surgically treated patients improved, but sev­
en of the patients who reveived radiation did. The authors’ 
conclusions were that radiation should be the treatment of 
choice and that a decompressive laminectomy is indicated 
in only three situations: 1) to establish a diagnosis; 2) to 
treat a relapse if the patient is unable to undergo further 
radiation therapy; and 3) if symptoms progress during 
radiation treatment.
Despite the obvious need and repeated requests for in­
vestigators to conduct a randomized controlled trial, only 
one has been attempted. Young, et al.,92 randomized pa­
tients who had a symptomatic epidural spinal lesion to 
groups receiving either laminectomy followed by radio­
therapy or radiotherapy alone. Sixteen patients were ran­
domized to the surgical arm, and 13 to the radiotherapy 
arm. No significant difference was found between the 
groups with respect to pain relief, ambulatory status, or 
sphincter function. There were no treatment-related com­
plications for surgery or radiotherapy. The major limita­
tion of their study, as the authors clearly stated, was that 
the patient group was too small for the au-thors to be able 
to detect a difference in the treatments. Rather, the major 
goal of that study was to demonstrate that a properly con­
ducted randomized controlled trial was feasible.
As a result of these articles and others listed in Table 4, 
laminectomy was viewed as a procedure with minimal 
neurological benefit and significant morbidity, and it was 
determined that radiation should assume the primary treat­
ment role. Indiscriminate use of decompressive laminec­
tomy was prone to failure because in most cases the tumor 
lies ventral to the thecal sac. This makes it impossible to 
accomplish a meaningful decompression or tumor resec­
tion without significant retraction of the thecal sac. Fur­
thermore, a laminectomy can cause or worsen preexisting 
spinal instability. This can lead to progressive deformity, 
which in turn can result in pain, more deformity, and neu­
rological compromise. Based on these data, we believe 
that decompressive laminectomy alone without supple­
mental internal fixation should not be used in patients with 
metastatic spinal disease, except in cases in which the dis­
ease is strictly confined to the lamina and spinous process. 
Despite the evidence, however, this procedure continues 
to be performed by some surgeons.74
The results of decompressive laminectomy seem to be 
improved if internal fixation (for example, pedicle screws) 
and fusion are performed as well. In a review of 134 pa­
tients treated with either a laminectomy (111 patients) or 
laminectomy with stabilization (23 patients), Sherman 
and Waddell,75 found that the latter group had better post­
treatment ambulatory status (92 compared with 57%), 
sphincter function, and pain control, and less recurrent 
neurological dysfunction. These findings have been sup­
ported by others.7,44,47’62’67’75
Surgery: Circumferential Spinal Cord Decompression
Best Level of Evidence, Class I; Level of Recommen­
dation, A. With the failure of laminectomy, the primary 
treatment for metastatic disease has been largely confined 
to radiation therapy. Nevertheless, a new philosophy on
the surgical management of metastatic spinal disease has 
emerged. In his 1984 article, Findlay23 reviewed the small 
amount of data on anterior spinal surgery and found “dra­
matic results” with regard to neurological function, but 
warned that “ . . . it is unclear as to how often such success 
could be achieved.” As surgeons realized the limitations 
of the laminectomy, they began to decompress the ventral 
spinal cord, which is the most common site of metastatic 
spread. Thus, a new treatment protocol began to emerge— 
circumferential spinal cord decompression.
To achieve a circumferential decompression, surgical 
approaches must be tailored to the location of the tumor 
with respect to the spinal cord. The end result is to free the 
spinal cord of any malignant compression. Approaches 
can be broadly classified as anterior (for example, trans- 
thoracic or retroperitoneal) or posterior, including pos­
terolateral trajectories (for example, laminectomy, trans- 
pedicular, costotransversectomy, or lateral extracavitary). 
In addition to spinal cord decompression, reconstruction 
and immediate stabilization of the spinal column form the 
pillars of surgical management today.
A large amount of literature has emerged over the last 
20 years; this is summarized in Table 5. Although the arti­
cles on circumferential decompression are generally more 
detailed than their laminectomy counterparts, they still are 
uncontrolled cohort studies and thus represent Class III 
data. In one of the largest reports Sundaresan, et al.,81 
described their results in 80 patients who had solitary met­
astatic spinal lesions. Depending on the anatomical and 
radiological findings on the extent of the tumor, they used 
a variety of approaches: an anterior approach was used in 
32 patients, a strictly posterior or posterolateral approach 
was used in eight, and a combined anteroposterior ap­
proach was used in 40. Preoperatively, 48 patients (60%) 
were ambulatory and 55 (69%) experienced a significant 
amount of pain. Postoperatively, 78 (98%) were ambula­
tory, including 94% of those who were initially nonambu­
latory. Pain was improved in 95%, with 76% reporting 
complete relief. Although the overall survival duration 
was 30 months, there was a considerable range among the 
various tumor types. Patients with breast and renal cell 
carcinoma had a median survival duration of 36 months, 
compared with 15 and 12 months for gastrointestinal and 
unknown primary carcinoma, respectively.
Gokaslan, et al.,31 reported their results with transtho- 
racic vertebrectomy in 72 patients. Pain was improved in 
92% of patients, and 93% were able to walk postopera­
tively. Of the 13 patients who were nonambulatory preop- 
eratively, 10 regained ambulatory ability after surgery, 
with three of them regaining normal function. The 1-year 
survival rate for the entire cohort was 62%. Overall, the 
data seem to indicate that neurological outcomes are far 
superior to those that are achieved with decompressive 
laminectomy and/or radiation. Not surprisingly, the mor­
bidity and mortality rates associated with this more ag­
gressive surgical management are significant (Table 5).
Analogous to the controversy of laminectomy com­
pared with radiation in the “old era,” it is clear that a 
randomized controlled trial is needed to address more ad­
equately the question of the effectiveness of circumfer­
ential decompressive surgery compared with radiation in 
this “new era.” At the 2003 annual meeting of the Amer-
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TABLE 5
Literature review o f results o f circumferential spinal cord decompression in patients with metastasis*
Postoperative Results (%) Complications!
No. of Pain (% % or
Authors & Year Patients improved) Success Rescue Type No.
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TABLE 5, Continued
Literature review o f results o f circumferential spinal cord decompression in patients with metastasis*
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* “Success” is defined as the proportion of patients who were ambulatory after treatment, whereas “rescue” is the proportion of nonambulatory patients 
who regained ambulatory function, either with assistance or independently. Abbreviations: NA = not available.
f  Mortality and morbidity are defined as occurrence of death or complication within 30 days of the operation. Morbidity is the number of complications 
divided by the number of patients in the study. Thus, overestimates may arise if one patient suffered more than one complication. The number of patients 
with each type of complication is recorded. Surgical complications include wound infection, hematomas, cerebrospinal fluid leaks, and so on. Examples of 
hardware complications include broken screws and graft migration/dislodgement. Medical complications are those that are not directly related to the surgery, 
such as pneumonia, myocardial infarction, deep venous thrombosis/pulmonary embolism, and so on. Patients who suffered new neurological deficits were 
considered to have neurological complications. Local recurrence and pseudarthrosis were not counted as complications.
ican Society of Clinical Oncology, Patchell, et al.,63 pre­
sented the results of their randomized, controlled trial, in 
which they compared direct, decompressive resection fol­
lowed by adjuvant radiation with conventional radiation 
alone. Both groups were treated with the same steroid pro­
tocol and both received the same total radiation dose (30 
Gy). There were 50 patients in the surgical arm and 51 in 
the radiation arm of the study. Patients treated with 
surgery retained ambulatory and sphincter function signif­
icantly longer than patients in the radiation group. Also, 
56% of nonambulatory patients in the surgical group 
regained the ability to walk, compared with 19% in the 
radiation group. Survival was not significantly different 
between the two groups.
This landmark study represents the first good Class I 
data in the metastatic spinal disease literature. Our review 
of the literature supports a change in the current manage­
ment protocols for metastatic epidural spinal disease. Tra­
ditional indications for surgery include radiation-resistant 
tumors (sarcoma, lung, colon, and renal cell); obvious 
spinal instability; clinically significant neural compres­
sion secondary to retropulsed bone or from spinal de­
formity; intractable pain unresponsive to medical treat­
ment; and failure of radiation therapy (progression of def­
icit during treatment or spinal cord tolerance reached). We 
believe that surgery should be considered the primary 
treatment modality in all patients with newly diagnosed 
metastatic disease who do not have any of the indications 
for radiotherapy (see Conventional Radiation Therapy).
Conventional Radiation therapy
Best Level of Evidence, Class I; Level of Recommenda­
tion, A. Indications for radiotherapy are as follows: radio­
sensitive tumors (lymphoma, multiple myeloma, small­
cell lung carcinoma, seminoma of testes, neuroblastoma, 
and Ewing sarcoma); expected survival less than 3 or 4 
months; patient unable to tolerate an operation; total neu­
rological deficit below the level of compression for more 
than 24 to 48 hours; and multilevel or diffuse spinal in­
volvement. The standard radiation portal involves the dis­
eased level with a 5-cm margin, which effectively in­
cludes two VBs above and below.53 The total radiation
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dosage is usually 3000 cGy (2000-4000 cGy) and is ad­
ministered over a 10- to 14-day course, with higher doses 
delivered in the first few days and then tapered down. 
Patients with radiosensitive tumors (breast, myeloma, or 
lymphoma) have a better functional outcome overall than 
those who have more radiation-resistant tumors (sarcoma, 
lung, colon, or renal cell). In many patients the disease is 
isolated in the spine, usually the VB, without epidural 
compression. For these patients, a single dose (usually 8 
Gy) provides good pain relief and is as efficacious as var­
ious fractionated regimens.42,43
Table 4 depicts the results of radiation therapy during 
the era in which decompressive laminectomy was the pre­
dominant surgical procedure. There have been a number 
of reports since then, all uncontrolled cohort studies, 
which are shown in Table 6. One of the largest reports is 
by Maranzano and colleagues.51,56,57 They treated 209 pa­
tients with radiation (30 Gy) and steroid drugs. Pain was 
present in 98% of patients and 65% had some degree of 
neurological dysfunction. The mean follow-up duration 
was 49 months. Pain improved in 71% of patients, ambu­
latory function improved in 36%, and bladder function 
improved in 44%. Overall, 76% recovered or preserved 
their ability to walk. The median survival duration for the 
whole group was 6 months, with a 1-year survival rate of 
28%. Favorable factors for survival included ambulatory 
status, both before and after treatment, and histological 
findings.
Helweg-Larsen40 followed 153 patients for a median of 
2.6 months. Normal gait was present in 60 patients (39%), 
assisted ambulation in 19 (12%), paresis without gait 
function was found in 31 (20%), and paraplegia was found 
in 43 (29%). Neurogenic bladder was present in 57 pa­
tients (37%). The total radiation dose was 28 Gy, which 
was given in fractions of 4 Gy on 7 consecutive days. In 
total, 21 of the 74 initially nonambulatory patients (12 
paretic, nine plegic) recovered some gait function. Seven 
patients (two with normal gait, five who needed assistance 
walking) deteriorated to a nonambulatory state because of 
treatment failure. Of those patients who presented with 
sphincter dysfunction, 10 (18%) regained bladder func­
tion. The median survival duration was 5.4 months.
As stated previously, the recently released results of the 
first well-designed, randomized, controlled trial compar­
ing stand-alone radiotherapy to surgery with adjuvant ra­
diotherapy show a marked benefit for surgery.63 Thus, for
TABLE 6









Leviov, et al., 1993) 70 NA 39 4
Maranzano & Latini, 1995 209 71 76 51
Helweg-Larsen, 1996 153 83 61 28
Katagiri, et al., 1998 101 57 64 19
Chamberlain & Kormanik, 1999 108 75 NA 5
Rades, et al., 2002 98 NA 60 NA
Zaidat & Ruff, 2002 139 100 78 47
patients who meet surgical criteria, the role of standard 
radiotherapy is as adjuvant therapy only. Conversely, there 
are many patients who either cannot tolerate surgery or in 
whom it would be inappropriate (for example, in high­
ly radiosensitive tumors in patients with a short life ex­
pectancy). In these patients, radiation should still serve as 
the primary mode of treatment.
Nonconventional Radiation Therapy
Best Level of Evidence, Class III; Level of Recom­
mendation, C. With conventional external beam radiation, 
a significant amount of healthy tissue is exposed to radia­
tion, including the spinal cord, which can lead to ra­
diation-induced myelopathy48,83,85 Therefore, if radiation 
could be delivered to the target while decreasing the 
amount delivered to healthy tissue, injuries to the spinal 
cord would theoretically be reduced. Nonconventional 
radiotherapy, which includes stereotactic radiosurgery and 
intensity-modulated radiotherapy, is able to do just that. 
The currently available data represent case series (Class 
III) evidence.27,69-71 The follow up is short and outcome 
measures, such as neurological function, are rarely dis­
cussed. The research so far has shown nonconventional 
radiation therapy to be a safe intervention; however, its 
effectiveness has not been rigorously tested against other 
current therapies (surgery or conventional radiotherapy). 
Such data are needed before a treatment recommendation 
can be rendered.
CONCLUSIONS
Treatment of metastatic epidural spinal disease has 
undergone significant changes over the last 20 years. No 
longer is indiscriminant decompressive laminectomy of­
fered as the only surgical treatment. It carries all the risks 
associated with an invasive procedure and offers the pa­
tient little benefit, unless it is used to remove tumors iso­
lated in the posterior elements. From the existing literature 
we infer that surgery that frees the spinal cord at the site 
of compression, in addition to reconstructing and stabiliz­
ing the spinal column, is more effective at preserving and 
regaining neural function, notably ambulatory and sphinc­
ter function, than conventional radiotherapy. This type of 
surgery is also highly effective in relieving pain. The pre­
liminary results of a recent randomized, controlled trial 
provide the first Class I evidence to support a reversal in 
the current trend toward primary treatment for many pa­
tients with metastatic disease. Conventional radiotherapy 
has a clearly defined role as adjuvant therapy, as well as 
primary therapy in those who are unable to tolerate or ben­
efit significantly from surgery. The role of nonconven- 
tional radiation therapy, such as intensity-modulated ra­
diotherapy and stereotactic radiosurgery, remains to be 
elucidated.
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